INCYTE GENOMICS INC
8-K, 2000-12-21
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: VAN KAMPEN CALIFORNIA QUALITY MUNICIPAL TRUST, N-30D, 2000-12-21
Next: INCYTE GENOMICS INC, 8-K, EX-99, 2000-12-21







                    SECURITIES  AND  EXCHANGE  COMMISSION


                           WASHINGTON,  D.C.  20549

                                 ____________



                                   FORM  8-K



                                CURRENT  REPORT



               PURSUANT  TO  SECTION  13  OR  15(D)  OF  THE
                     SECURITIES  EXCHANGE  ACT  OF  1934


                    DATE  OF  REPORT:  DECEMBER  21,  2000
                    (Date  of  earliest  event  reported)


                             INCYTE  GENOMICS,  INC.
        (Exact  name  of  registrant  as  specified  in  its  charter)


                  DELAWARE                  0-27488           94-3136539
      (State  or  other  jurisdiction     (Commission        (IRS  Employer
           of  incorporation)           File  Number)    Identification  No.)


               3160  PORTER  DRIVE,  PALO  ALTO,  CALIFORNIA    94304
           (Address  of  principal  executive  offices)       (Zip  Code)


Registrant's  telephone  number,  including  area  code:  (650)  855-0555


<PAGE>

Item  5.     Other  Events.
             -------------

(a)     On  December  21,  2000, Incyte Genomics, Inc. (the "Company") announced
that  it  entered  into an agreement to acquire Proteome, Inc., a privately held
company  based  in  Beverly,  Massachusetts.  A  copy  of  the  press release is
attached  hereto  as  Exhibit  99.1  and  is  incorporated  by reference herein.


(b)     The 2001 Annual Meeting of Incyte Genomics, Inc. (the "Company") will be
held  on  June  5,  2001  at  such  place  and  time as will be set forth in the
Company's  proxy statement relating to that meeting.  A stockholder proposal not
included  in  the  proxy statement for the Company's 2001 Annual Meeting will be
ineligible  for  presentation at the meeting unless the stockholder gives timely
notice  of  the  proposal  in  writing  to  the  Secretary of the Company at the
principal  executive  offices  of  the  Company  and otherwise complies with the
provisions  of the Company's Bylaws.  To be timely, the Company's Bylaws provide
that  the  Company  must have received the stockholder's notice not less than 60
days  nor  more  than  90  days  prior  to  the  scheduled date of such meeting.
However,  if notice or prior public disclosure of the date of the annual meeting
is  given  or  made to stockholders less than 70 days prior to the meeting date,
the  Company  must  receive  the  stockholder's notice by the earlier of (i) the
close  of  business  on  the  10th  day after the earlier of the day the Company
mailed  notice  of the annual meeting date or provided such public disclosure of
the  meeting  date  and  (ii) two days prior to the scheduled date of the annual
meeting.   For  the  Company's 2001 Annual Meeting of Stockholders, stockholders
must  submit  written  notice  to the Secretary in accordance with the foregoing
Bylaw  provisions  no  later  than  April  6,  2001.

Item  7.     Financial  Statements  and  Exhibits.
             ------------------------------------

(c)     Exhibits

     99.1     Press  Release  dated  December  21,  2000.

<PAGE>


                                    SIGNATURE


     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.


     Dated:  December  21,  2000


                                 INCYTE  GENOMICS,  INC.



                                 By:    /s/  John  M.  Vuko
                                        -------------------
                                 Name:  John  M.  Vuko
                                 Title: Chief  Financial  Officer






© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission